Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biotin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | IDE | P14735 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.85 |
| ▸ | HLCS | P50747 | 6/20 | 0.64 |
| ▸ | CA12 | O43570 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 7/20 | 0.53 |
| ▸ | CA2 | P00918 | 7/20 | 0.53 |
| ▸ | CA9 | Q16790 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL3425472 | 1.00 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL739967 | 1.00 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL16653090 | 0.99 | TDP1 (0.83) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6865574 | 0.96 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL27481189 | 0.95 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL453833 | 0.95 | TDP1 (0.90) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8672971 | 0.94 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8432238 | 0.94 | TDP1 (0.76) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL2057282 | 0.94 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16141190 | 0.94 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050329-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MAN LLC (US) | 2024-02-15 | — | — | US | claimed |
| CN-111333664-A | Biotin cross-linking agent, application and preparation method thereof | 苏州昊帆生物股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-0222889-B1 | CYTIDINE ANALOGS | AMOCO CORP (US) | 1993-10-27 | — | — | EP | claimed |
| EP-0222889-A4 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1988-09-28 | — | — | EP | claimed |
| EP-0222889-A1 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1986006726-A1 | CYTIDINE ANALOGS | INTEGRATED GENETICS, INC. (US) | 1986-11-20 | — | — | WO | claimed |
| US-20240050329-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MAN LLC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4041185-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC Management LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114630840-A | Novel anti-CLDN 18.2 antibodies | 苏州创胜医药集团有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021072332-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MANAGEMENT LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210106506-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MANAGEMENT LLC | 2021-04-15 | — | — | US | disclosed |
| EP-0256932-B1 | USE OF OXIDASE ENZYME SYSTEMS IN CHEMILUMINESCENT ASSAYS | CANBERRA INDUSTRIES, INC. (US) | 1993-03-10 | — | — | EP | disclosed |
| US-5108893-A | Oxidase, while produces peroxides an superoxide anions, reacting with substrate, chemiluminescent reagent and enhancer emitted light | CANBERRA INDUSTRIES, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| US-4933276-A | Use of oxidase enzyme systems in chemiluminescent assays | CANBERRA INDUSTRIES, INC. (US) | 1990-06-12 | — | — | US | disclosed |
| EP-0222889-A4 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0256932-A2 | Use of oxidase enzyme systems in chemiluminescent assays | CANBERRA INDUSTRIES, INC. (US) | 1988-02-24 | — | — | EP | disclosed |
| EP-0222889-A1 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1987-05-27 | — | — | EP | disclosed |
| WO-1986006726-A1 | CYTIDINE ANALOGS | INTEGRATED GENETICS, INC. (US) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | TDP1 174/4885MEN1 630/4885ABL1 4449/4885 |
| US-20240050329-A1 | METHODS FOR COSMETIC SKIN REMODELING | CUTA, PLOD3, KRT18 | TDP1 612/4885MEN1 2593/4885ABL1 4735/4885 |
| US-20210106506-A1 | METHODS FOR COSMETIC SKIN REMODELING | CUTA, PLOD3, KRT18 | TDP1 612/4885MEN1 2593/4885ABL1 4735/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | TDP1 174/4885MEN1 630/4885ABL1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.